Mitochondrial quality control mechanisms as therapeutic targets in doxorubicin-induced cardiotoxicity

Area of Science:

• Cardiovascular research
• Mitochondrial biology
• Pharmacology

Background:

• Doxorubicin (DOX) is a vital chemotherapy drug for various cancers.
• DOX treatment often leads to severe cardiotoxicity, manifesting as heart failure.
• Mitochondrial dysfunction is increasingly recognized in DOX-induced heart damage.

Purpose of the Study:

• To elucidate the role of mitochondrial quality control in DOX cardiotoxicity.
• To explore therapeutic strategies targeting mitochondrial pathways to mitigate DOX-induced heart damage.

Main Methods:

• Review of current literature on mitochondrial quality control and DOX cardiotoxicity.
• Analysis of mechanisms underlying DOX-induced mitochondrial dysfunction.
• Evaluation of potential therapeutic interventions targeting mitochondrial quality control.

Main Results:

• Defective mitochondrial proteostasis, mitophagy, dynamics, and biogenesis are implicated in DOX cardiomyopathy.
• Interventions aimed at preserving mitochondrial function show promise in preclinical models.
• Clinical application of these strategies is limited by unclear mechanisms and potential side effects.

Conclusions:

• Mitochondrial quality control is a critical factor in the development of DOX cardiotoxicity.
• Targeting mitochondrial quality control pathways represents a promising avenue for novel therapeutic strategies.
• Further research is needed to clarify mechanisms and ensure safe clinical translation.